Dr. Mark Bodmer, Ph.D. has been Chief Scientific Officer and President of R&D at Evelo Biosciences, Inc. since April, 2016. Dr. Bodmer served as Head of New Medicines Therapeutics at UCB, leading UCB's research in immunology, neurology and bone disease. Prior to joining UCB, he served as Senior Vice President of Immunoinflammation, at GlaxoSmithKline, where he was also previously Head of Metabolic and Cardiovascular Disease Drug Discovery. From 2000-2007 Dr. Bodmer served as the Chief Executive Officer of Biotica Technology and Lorantis. Dr. Bodmer served as the Head of Research & Development of Incyte Pharmaceuticals and President of its European subsidiary until November 30, 1999. He served as the Founding Chief Executive Officer of Hexagen since 1996. He served as Director of Biology of Celltech Therapeutics since 1994. Dr. Bodmer joined Celltech group plc, where he held a number of research and development roles. He received a Ph.D. in Genetics from Cambridge University in 1982.